Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies

Following our recent observation that alterations of the Natural Killer (NK) cell compartment in the presence of BCR-ABL-induced myeloproliferation fail to revert under targeted therapy, we discuss by what mechanisms oncogenic molecular pathways and their pharmacological inhibition may interfere wit...

Descripción completa

Detalles Bibliográficos
Autor principal: Rossig, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382876/
https://www.ncbi.nlm.nih.gov/pubmed/22737614
http://dx.doi.org/10.4161/onci.18401
_version_ 1782236565287731200
author Rossig, Claudia
author_facet Rossig, Claudia
author_sort Rossig, Claudia
collection PubMed
description Following our recent observation that alterations of the Natural Killer (NK) cell compartment in the presence of BCR-ABL-induced myeloproliferation fail to revert under targeted therapy, we discuss by what mechanisms oncogenic molecular pathways and their pharmacological inhibition may interfere with immune functions. Rational combinations of molecularly targeted and immunological strategies may provide a means for more effective cancer targeting.
format Online
Article
Text
id pubmed-3382876
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33828762012-06-26 Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies Rossig, Claudia Oncoimmunology Author's View Following our recent observation that alterations of the Natural Killer (NK) cell compartment in the presence of BCR-ABL-induced myeloproliferation fail to revert under targeted therapy, we discuss by what mechanisms oncogenic molecular pathways and their pharmacological inhibition may interfere with immune functions. Rational combinations of molecularly targeted and immunological strategies may provide a means for more effective cancer targeting. Landes Bioscience 2012-05-01 /pmc/articles/PMC3382876/ /pubmed/22737614 http://dx.doi.org/10.4161/onci.18401 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Rossig, Claudia
Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
title Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
title_full Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
title_fullStr Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
title_full_unstemmed Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
title_short Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
title_sort immune modulation by molecular cancer targets and targeted therapies: rationale for novel combination strategies
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382876/
https://www.ncbi.nlm.nih.gov/pubmed/22737614
http://dx.doi.org/10.4161/onci.18401
work_keys_str_mv AT rossigclaudia immunemodulationbymolecularcancertargetsandtargetedtherapiesrationalefornovelcombinationstrategies

Ejemplares similares